Usefulness of lyso-globotriaosylsphingosine in dried blood spots in the differential diagnosis between multiple sclerosis and Anderson–Fabry's disease

•LysoGb3 is not elevated in patients whith multiple sclerosis.•The cut-off point 3.5 ng/mL, for LysoGb3 in DBS, is valid to rule out Fabry disease.•If demyelinating lesions are present LysoGb3 is enough to discard Fabry disease. The presence of white mater lesions in the central nervous system force...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2020-02, Vol.38, p.101466-101466, Article 101466
Main Authors: Olivera, Susana, Iñiguez, Cristina, García-Fernández, Lorena, Sierra, José-Luis, Camón, Ana-María, Menao, Sebastián, Torralba, Miguel-Ángel
Format: Article
Language:English
Subjects:
Aged
Anderson-Fabry
Biomarkers
Biomarkers - blood
Diagnosis, Differential
Differential diagnosis
Dried blood spot
Dried Blood Spot Testing
Fabry Disease - blood
Fabry Disease - diagnosis
Female
Glycolipids - blood
Humans
Lyso-globotriaosylsphingosine
Male
Middle Aged
Multiple sclerosis
Multiple Sclerosis - blood
Multiple Sclerosis - diagnosis
Sphingolipids - blood
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•LysoGb3 is not elevated in patients whith multiple sclerosis.•The cut-off point 3.5 ng/mL, for LysoGb3 in DBS, is valid to rule out Fabry disease.•If demyelinating lesions are present LysoGb3 is enough to discard Fabry disease. The presence of white mater lesions in the central nervous system forces the differential diagnosis between multiple sclerosis (MS) and Anderson–Fabry disease (FD). Due to the type of inheritance, linked to the X chromosome, the diagnosis of FD is especially difficult in women. Tissue´s deposits of globotriaosylceramide (Gb3) are characteristics for FD and the deacylated form of Gb3 (Globotriaosylsphingosine or LysoGb3) is specific for this entity. Our objective is to investigate if concentrations of plasma Lyso-Gb3 are useful for ruling out the FD in a Spanish cohort of patients with a previous diagnosis of MS. we evaluated the α-galactosidase A enzymatic activity in 154 patients with a previous diagnosis of MS (93 women and 61 men): 103 Relapsing Remitting MS patients, 19 progressive MS patients and 32 with the clinically isolated syndrome. 116 (75% of the patients) were on MS disease modifying therapy. Enzymatic assay was completed in all cases and done on dried blood spot (DBS) samples. Subsequently the GLA gene was sequenced only in males and females who presented an enzymatic assay significantly lower than standardized controls (
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2019.101466